Jane Hollingsworth J.D.

Non-Executive Director


Jane is the founding Managing Partner of Militia Hill Ventures (MHV), a US based organization that creates, builds and invests in life sciences companies.  While at MHV, Jane has co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc. (NASDAQ: IMNM), a cancer immunotherapy company.

Prior to MHV, Jane was co-founder and CEO of NuPathe Inc. (NASDAQ: PATH), a neuroscience focused biopharmaceutical company which was sold to Teva. She also co-founded and served as EVP of Auxilium Pharmaceuticals (NASDAQ: AUXL), an urology and rare disease focused biopharmaceutical company which was sold to Endo Pharmaceuticals.

Prior to founding and leading multiple biopharmaceutical companies, Ms. Hollingsworth was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization. Before joining IBAH, Jane practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.